Cowden syndrome: a critical review of the clinical literature.

Department of Internal Medicine and Clinical Cancer Genetics Program, Comprehensive Cancer Center, James Cancer Hospital and Solove Research Institute, Ohio State University, Columbus, OH 43221, USA.
Journal of Genetic Counseling (Impact Factor: 1.75). 11/2008; 18(1):13-27. DOI: 10.1007/s10897-008-9187-7
Source: PubMed

ABSTRACT Cowden syndrome (CS) is a multi-system disease involving hamartomatous overgrowth of tissues of all three embryonic origins and increased risks for thyroid, breast and possibly other cancers. Benign breast, thyroid, uterine and skin lesions are also common. Approximately 80% of patients with CS have an identifiable germline mutation in the PTEN gene. The majority of the existing data on the frequencies of component clinical features have been obtained from compilations of case reports in the literature, many of which predate the establishment in 1996 of consensus diagnostic criteria. Many of these reports also suffer from ascertainment bias which emphasized the dermatologic features of the disease. This paper presents an overview of Cowden syndrome focusing on a critical evaluation of the major literature on the component cancers, benign features, and molecular findings in CS, noting the limitations of the published data.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Le gangliocytome du cervelet peut correspondre à la maladie de Lhermitte-Duclos, malformation hamartomateuse bénigne de l’adulte jeune, ou appartenir au groupe des gangliogliomes/gangliocytomes, tumeurs habituellement temporales de l’enfant qui se manifestent par des crises comitiales. Nous décrivons le cas d’un jeune garçon de 11 ans ayant présenté un gangliocytome du cervelet découvert devant un tableau neurologique comportant des céphalées, une dyspraxie et des troubles de l’équilibre et de la marche. Le diagnostic a été porté sur le matériel chirurgical d’exérèse. La tumeur correspondait à une population de cellules ganglionnaires matures d’aspect dysplasique, accompagnée d’infiltrats inflammatoires lymphocytaires périvasculaires et sans contingent tumoral glial identifié. En immunohistochimie, les cellules ganglionnaires exprimaient les neurofilaments, la protéine MAP2, la synaptophysine, la chromogranine A et la protéine S100. La mutation V600E de BRAF n’a pas été détectée. Les caractéristiques cliniques, radiologiques, histopathologiques des deux principaux diagnostics sont discutées.
    Annales de Pathologie 11/2014; · 0.29 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Only 5% of breast cancers are explained by highly penetrant multisystem autosomal dominant hereditary disorders. Though another 20–30% has a familial presentation, the genetic and other etiologies are still not well understood. Genetic testing is now widely available and multiple professional societies have published guidelines for testing and management. Genetic testing trends include utilization of multi-gene panels that take advantage of next-generation sequencing as well as testing for low- and moderate-penetrance susceptibility genes. J. Surg. Oncol. © 2014 Wiley Periodicals, Inc.
    Journal of Surgical Oncology 11/2014; · 2.84 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This guideline presents recommendations for the management of patients with hereditary gastrointestinal cancer syndromes. The initial assessment is the collection of a family history of cancers and premalignant gastrointestinal conditions and should provide enough information to develop a preliminary determination of the risk of a familial predisposition to cancer. Age at diagnosis and lineage (maternal and/or paternal) should be documented for all diagnoses, especially in first- and second-degree relatives. When indicated, genetic testing for a germline mutation should be done on the most informative candidate(s) identified through the family history evaluation and/or tumor analysis to confirm a diagnosis and allow for predictive testing of at-risk relatives. Genetic testing should be conducted in the context of pre- and post-test genetic counseling to ensure the patient's informed decision making. Patients who meet clinical criteria for a syndrome as well as those with identified pathogenic germline mutations should receive appropriate surveillance measures in order to minimize their overall risk of developing syndrome-specific cancers. This guideline specifically discusses genetic testing and management of Lynch syndrome, familial adenomatous polyposis (FAP), attenuated familial adenomatous polyposis (AFAP), MUTYH-associated polyposis (MAP), Peutz-Jeghers syndrome, juvenile polyposis syndrome, Cowden syndrome, serrated (hyperplastic) polyposis syndrome, hereditary pancreatic cancer, and hereditary gastric cancer.
    The American Journal of Gastroenterology 02/2015; 110(2):223-62. · 9.21 Impact Factor